Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limitjed

Toshiaki Nagata

Tomomi Ikemoto

Tsuneo Yasuma

Naohiro Fukuda

Takeshi Yamasaki

Isao Aoki

Mitsuhisa Yamano

Atsuo Baba

Haruhiko Makino

Misayo Sera

Hideki Saito

Mitsuru Nonogawa

Hideya Mizufune

Hideki Saitoh

Tsuneo Kanamaru

Kazuo Nakahama

Naoki Tarui

Masakuni Kori

Motowo Izawa

Kiyoharu Matsumoto

Yoichi Nagano

The present invention provides a production method for 5-Aryl-1H-Pyrolle-3-Carbontirile compounds: The productions method provides key intermediates useful for a method of preparing additional pyrrole compounds useful as a pharmaceutical product, particularly an acid secretion inhibitor, a productions method of an intermediate used for this method, a novel intermediate, and the like.

Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation

The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction. 

Process for producing pyrrole compound

In this method, an oligonucleotide represented by formula (II) [wherein Y, Q, Base, r and r' are each as defined in claim] is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R, Y, Base, Z, Ar, R, Rand n are each as defined in claim]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method can dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3&#x2032;-direction but also in the 5&#x2032;-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide. 

Method for liquid-phase synthesis of nucleic acid

The present invention relates to a graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof (e.g., a graft copolymer (&#x3b3;-PGA-PAE) of poly(&#x3b3;-glutamic acid) (&#x3b3;-PGA) and phenylalanine ethyl ester (PAE)), an ionized graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof, nanoparticles containing the ionized graft copolymer, and a production method thereof. The nanoparticles acquired in this way are useful as an adjuvant for producing a vaccine.

Production method for poly(amino acid)

In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R, Y, Base, Z, Ar, R, Rand n are each as defined in Claim]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method cars dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3'-direction but also in the 5&#x2032;-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide. 

5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same

The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I): wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, &#x2014;(CH)&#x2014;, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of (wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.

Thienopyridine derivatives, their production and use

A process for producing an optically active form of a compound of formula (I) ##STR1## wherein R.sub.1 represents hydrogen or a hydrocarbon group that may be substituted; R.sub.2 and R.sub.3 independently represent hydrogen, a hydrocarbon group that may be substituted, or a heteroaromatic group that may be substituted; X' represents a substituent comprising an esterified carboxyl group or an acylated hydroxyl group; ring A represents a benzene ring that may be substituted or a heteroaromatic ring that may be substituted; ring J' represents a 7- or 8-membered heterocyclic ring containing at most 3 hetero-atoms as ring-constituent members, which may have a further substituent or substituents in addition to R.sub.1, R.sub.2, R.sub.3 and X', and C* denotes a chiral carbon atom or a salt thereof, which comprises subjecting the racemic compound of the formula (I) or a salt thereof, or alternatively a racemic starting compound for synthesizing the compound of the formula (I) to enzymatically enantioselective hydrolysis to provide an optically active form thereof.

Process for enantioselective hydrolysis of

Growing community of inventors

Osaka, Japan

Toshiaki Nagata